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Background: The cost-effectiveness of universal rotavirus (RV) vaccination is controversial in developed countries.
As a result, RV vaccination programs do not currently exist in most European countries. Hospitalization is the main
driver of RV disease costs, and prematurity, low birth weight (LBW) and underlying medical conditions have been
associated with RV hospitalization and complications. We investigated the cost-effectiveness of targeted RV
vaccination of high-risk infants and universal RV vaccination versus no vaccination.
Methods: Disease burden, mortality and healthcare costs of RV hospitalization for children with and without
prematurity, LBW and congenital pathology were quantified in two hospital-based observational studies in the
Netherlands. Cost-effectiveness analysis was based on an age-structured stochastic multi-cohort model of the Dutch
population comparing universal RV vaccination and targeted vaccination of high-risk infants to no vaccination. The
primary endpoint was the incremental cost-effectiveness ratio (ICER), with a threshold of €35,000/quality-adjusted
life year (QALY) from the healthcare provider perspective. Sensitivity analyses included vaccine price and coverage,
herd-immunity and QALY losses.
Results: A total of 936 children with RV infection were included. Prematurity, LBW and congenital pathology were
associated with increased risks of RV hospitalization (relative risks (RR) ranging from 1.6 to 4.4), ICU admission (RR
ranging from 4.2 to 7.9), prolonged hospital stay (1.5 to 3.0 excess days) and higher healthcare costs (€648 to
€1,533 excess costs). Seven children succumbed due to RV complications, all belonging to the high-risk population.
Targeted RV vaccination was highly cost-effective and potentially cost-saving from the healthcare provider
perspective with ICERs below €20,000/QALY in all scenarios with total (undiscounted) annual healthcare costs
between -€0.1 and €0.5 million/year. Results were most sensitive to mortality rates, but targeted vaccination
remained highly cost-effective up to reductions of 90% compared to observed mortality. Universal RV vaccination
was not considered cost-effective (mean ICER: €60,200/QALY) unless herd-immunity and caretaker QALY losses were
included and vaccine prices were €60 at most (mean ICER: €21,309/QALY).
Conclusion: We recommend targeted RV vaccination for high-risk infants in developed countries.
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Rotavirus (RV) vaccination reduces severe RV gastroenter-
itis (GE), associated healthcare utilization and mortality
among young children [1,2]. Universal infant vaccination
with either the monovalent life-attenuated vaccine (RV1)
or the pentavalent human-bovine reassortant vaccine
(RV5) has, therefore, been recommended by professional
healthcare organizations worldwide [3-7] but results of
cost-effectiveness analyses of RV vaccination in developed
countries yielded conflicting results [8-11]. Consequently,
RV vaccination programs have been introduced in only a
very limited number of European countries [12].
Although RV is widely considered a universal pediatric
infection with young age as the only important risk factor,
in the developed world hospitalization due to RV, the
main driver of RV associated healthcare costs, seems to be
associated with underlying chronic disease, congenital dis-
orders, prematurity and low-birth weight (LBW) [13-24].
Moreover, these children are more prone to complicated
RV disease courses with more frequent ICU admission
[18]. RV infection in premature or LBW infants has been
associated with necrotizing enterocolitis, encephalopathy
[25-29] and increased diarrheal mortality [30-32].
A targeted vaccination strategy for RV, in which vaccin-
ation is offered to high-risk infants only, has not been eco-
nomically evaluated thus far. We, therefore, set out to
determine the cost-effectiveness of such an approach in
the Netherlands, where universal RV vaccination has not
been implemented yet, similar to the situation in most
European countries. We first quantified RV related hospi-
talizations in the Netherlands and identified patient
groups at increased risk of RV hospitalization or with in-
creased healthcare needs when hospitalized. Subsequently,
these data were supplemented with relevant available epi-
demiological data to determine cost-effectiveness of both
universal and targeted RV vaccination strategies compared
to no vaccination from a healthcare provider perspective.
Methods
Rotavirus hospitalizations; observational study
The methodology of this study has been described else-
where [33]. In brief, laboratory confirmed RV related
pediatric hospitalizations occurring in four participating
hospitals (three general hospitals, one tertiary care center)
during a five-year period (December 2005 to November
2010) were retrospectively studied. RV underreporting was
subsequently assessed by hospital-based active surveillance
during the 2011 RV season in the same four hospitals [33].
A comprehensive chart review was performed for each
case extracting data on RV disease course, healthcare re-
source utilization and patient’s medical history to identify
conditions potentially associated with increased clinical
vulnerability, such as prematurity of <36 weeks gestational
age and/or LBW (<2,500 grams) and complex chronicconditions. Complex chronic conditions were those that
(1) are expected to last longer than 12 months and (2)
involve either several different organ systems or one organ
system severely enough to require specialty pediatric care
and hospitalization. This classification characterizes a
group of patients with increased healthcare needs and
mortality [34-36]. We further classified complex chronic
conditions into those with a congenital origin (that is,
severe congenital pathology) and those with onset
later in life.
Prevalence rates for prematurity/LBW and severe con-
genital pathology were also derived for the Dutch infant
population from national disease and birth registries, cover-
ing 96% of the Dutch infant population [37,38]. In addition,
a nested case–control study was performed to investigate if
the same conditions increased the risk of nosocomial RVGE
compared to otherwise healthy age-matched hospital
controls [see details in Additional file 1].
Healthcare resource utilization, assessed at the individual
patient level, was used for cost calculations, adapting stand-
ard cost prices and charges [see Additional file 1: Table S1]
[39,40]. Costs included hospitalization days, preceding
emergency department visits, contact isolation precautions
[41] and ambulance transportation. For nosocomial RVGE
costs for RV related excess hospitalization days were used
[33], or, when hospitalization was not prolonged, isolation
costs and RVGE related diagnostic and therapeutic costs.
This study was approved by institutional review board of
the University Medical Centre Utrecht.
Statistical analysis
The prevalence of prematurity/LBW and severe congenital
pathology among RV hospitalizations compared to the
general infant population were used to compute Risk Ratios
(RR). To account for the clustered study design and for
oversampling of tertiary-care hospitalizations compared to
their national share in pediatric hospitalizations (20%),
weighted prevalence estimates were calculated with
variance estimated using Taylor series linearization [42].
Rates of ICU admission and RV-related deaths were
compared between RV patients with and without potential
high-risk conditions by computing RR. Length of stay or
excess hospitalization days in the case of nosocomial
RVGE and healthcare costs were compared by t-test, using
the arithmetic mean despite the usually skewed distribu-
tion. The arithmetic mean is considered most informative
in evaluations designed to have an impact on medical
policy, because it is the total disease burden that is
important [43].
Any of the assessed risk factors (prematurity/LBW or
congenital pathology) that were associated with increased
risk of RV hospitalization, nosocomial RVGE, RV-related
death and/or increased length of stay were included to de-
termine eligibility for targeted vaccination, excluding those
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RV vaccination is contra-indicated [44].
Differential RV hospitalization rates were calculated
for eligible and ineligible children from RVGE numbers
adjusted for underreporting using weighted estimation
[42]. Similarly, weighted mean hospitalization costs for
community-acquired and nosocomial RV infections were
calculated among eligible and ineligible children.
Analyses were performed using R software, version
1.14.1.Model design
We used an age-structured, discrete time-event, stochastic
multi-cohort model of the Dutch population, as previously
described by Mangen et al. [45] to investigate the
cost-effectiveness of adding RV vaccination to the
Dutch infant immunization program under two scenarios:
(1) universal vaccination and (2) targeted vaccination of
high-risk infants.
Strategies were compared assuming an annual birth
cohort of 180,000 infants, equivalent to the 2010 Dutch
birth cohort. The effect of vaccination was modeled as a
reduction in RVGE and associated health outcomes in
vaccinated compared to non-vaccinated children between
0 and 15 years old with RV disease risk stratified by age
and time since vaccination [see Additional file 1: Figure
S1]. Time steps of one month were used for ages 0 to 11
months and of one year thereafter. Effects were modeled
over a time-horizon of 20 years with year one being the
start of either vaccination program. The model was
adapted to simulate targeted vaccination by splitting the
population into a vaccination eligible and an ineligible
fraction. We assumed no effect on adult RV infections
from any of the infant vaccination strategies.Model parameters
Estimates of RV infection rates, outpatient healthcare
visits and related direct and indirect healthcare costs for
different age-groups were derived from existing epidemio-
logical sources as previously described by Mangen et al.
(Table 1) [45]. Hospitalization rates and costs for children
eligible and ineligible for targeted vaccination and for
combined groups were derived from our multi-center
observational study.
Mortality due to RV was determined by combining
data from the multi-center observational study and from
another study in a Dutch tertiary-care hospital. In this
study RV-related mortality was determined for all children
who had died within three weeks of confirmed RV infec-
tion between 2000 and 2006. Conservative estimates were
used for national mortality figures, assuming that fatal
cases exclusively occurred among RV hospitalizations at
tertiary-care centers without underreporting.An expert panel of four pediatricians was consulted to
determine years of life lost (YLL) accountable to RV infec-
tion among observed fatal cases (Table 1). This approach
was used to take into account the reduced life expectancy
in children with complex chronic conditions.
We used Quality Adjusted Life Years (QALYs), the
product of the health-state utility and the length of time
in that state, to weigh losses as a result of RV episodes
requiring different levels of healthcare, similar to those used
in previous cost-effectiveness analyses [9,10,45]. QALY
losses due to RV mortality were based on YLL estimates for
observed fatal RV cases.
European vaccine efficacy data were used for age-
specific vaccination effects (Table 2) [53-56,63]. Linear
waning immunity was assumed for the third, fourth
and fifth year post-vaccination, and zero protection
thereafter. Rotavirus genotype distribution in the
Netherlands is comparable to the observed genotype
distribution in European vaccine efficacy trials. Over-
all, G1P [8] is the dominant strain and G2P [4], G3P
[8], G4P [8] and G9P [8] are common co-circulating
strains with year-to-year variability in strain distribu-
tion [52]. We assumed 88% adherence to vaccination
recommendations for both universal and targeted RV
vaccination, the observed current vaccine coverage in
neighboring Belgium where universal RV vaccination
was implemented in 2007 [64], and used coverage
rates from 65% to 97% in sensitivity analysis.
Vaccine costs for universal RV vaccination were based on
Rozenbaum et al. who assumed that tender processes lower
vaccine prices by almost 50% (€75 per vaccine course)
compared to the current free market price [10]. Targeted
vaccination was assumed to generate price reductions of
25% (€100 per vaccine course). We also included scenarios
with the free market price for both vaccination strategies.
We assumed vaccine doses would be administered during
routine immunization clinic visits at a standard application
fee of €6.44 per vaccination [45].
Indirect vaccination effects (herd-immunity) among
unvaccinated children were considered as part of the
sensitivity analysis (Table 1) [58-60]. No herd-immunity
was assumed in the case of targeted vaccination, as
vaccine coverage was considered too low for herd-
immunity to occur.
Cost-effectiveness analysis
Our primary perspective was that of the healthcare pro-
vider and a societal perspective was included in sensitivity
analysis taking non-healthcare costs into account, updated
from Mangen et al. with additional data on parental work
loss due to RV hospitalizations in children [65]. All costs
were converted to 2011 Euros. A 3% discount rate for costs
and benefits was used in base-case scenarios according to
World Health Organization (WHO) guidelines [66]. Other
Table 1 Parameters for model input




Birth cohort (%) 182,662 168,215 (92.1%) 14,448 (7.9%) - Statistics Netherlands [46],
Dutch Perinatal Registry
[38], Eurocat [37]
Published results on birth cohort size and prevalence of
high risk conditions
RV incidence
<1 year 18,075 (11,768; 22,932) Calculated Calculated Pert Community-based cohort
study [47]
Incidence based on simulations from original study data
updated to 2011 population size, see Mangen et al. for
details [45] Distribution among eligible and ineligible
based on relative size of each group in birth cohort
1 to 4 years 42,218 (24,711; 56,272)
5 to 64 years 147,997 (41,573;282,866)
5 to 9 years 6.2% of 5 to 64 years Based on age-distribution of cases 5 to 64 years
in original study data10 to 14 years 2.9% of 5–64 years
GP visits 0 to 1
years
21.2% (12.8; 26.5) Calculated Calculated Pert GP based cohort study
[48]
Percentage of all RV cases, based on simulations from
original GP study data, see Mangen et al. for details [45].
Distribution among eligible and ineligible based on
relative size of each group in birth cohort
GP visits 1 to 4
years
18.7% (16.4; 19.9)





Calculated 3,884 (3,244; 4,524) 491 (357; 626) Pert RoHo-study Weighted incidence estimation based on original
study data, see Bruijning-Verhagen et al. for details [33].
Nosocomial
(95% CI)
Calculated 227 (162; 293) 269 (172; 365) Pert RoHo-study Weighted incidence estimation based on original




Calculated 0.00 (0.00; 0.04) 0 81 (0.36; 1.46) Triangular RoHo study, External dataset
Sophia Children’s hospital
Observed mortality cases from both sources








































Table 1 Parameters for model input (Continued)




Mortality Calculated 80.7 minus
patient’s age
Simulated, whereby
assuming a life expectancy
of 1; 20; 41.3 minus
patient’s age with
probability of 1/3 eachb
Uniform Statistics Netherlands [46],
Expert opinion
For ineligible: Based on average life expectancy in the







Standard GP visits 29 Guidelines for health-
economic evaluations [39]
Standard Cost Prices. See Mangen et al. for




Prescriptions 40 Community-based cohort
study and GP based
cohort study [49,50]
See Mangen et al. [45]
Laboratory costs 73
Hospitalization Calculated 2,179 (2,027;2,330) 2,550 (2,508; 3,606) Pert RoHo study Weighted estimates from original study data,
see Additional file 1






Additional diapers Uniform Assumption See Mangen et al. [45]
GP visits Additional diapers and travel costs Guidelines for health-
economic evaluations [39]






31.11 Fixed Statistics Netherlands [48]
Guidelines for health-
economic evaluations [39]
See Mangen et al. [45]




0.93; 1.36; 0.84 for ages 0 to 4; 5 to 9 and 10 to 14 years respectively Uniform Community-based cohort
study and GP based
cohort study [49,50]
Dependent of patient-age. See Mangen et al. [45]
Hours of work loss
GP visits


















Table 1 Parameters for model input (Continued)








Based on the findings from Friesema et al. [52]
for children up to 18, Further details see
Mangen et al. [45]
Hours of work loss
Nosocomial
24.58 Based on the findings from Friesema et al. [52]
for children up to 18, adjusted for excess duration of
hospitalization among nosocomial in RoHo study
(2.7 versus 2.9 days)




30% (0% to 46%) - Triangular Observational studies




RV1 60; 75; 90 80; 100; 120 Previous CEA [10] For
Eligible: Assumption
Assumed tender Price










aincludes QALY’s lost by caretakers; ball observed fatal RV cases occurred among patients with severe congenital conditions associated with limited life-expectancy (LE). To generate valid estimates of life years lost (YLL)
due to RV for each fatal case, four pediatricians (PB, MF, MvH, NH) were individually asked to provide estimates of LE without RV infection based on the patient’s medical records. Pediatricians were requested to
estimate for each individual fatal RV case the probability that LE without RV would have been ≤1 year, 1 to 20, 20 to 40 years or comparable to healthy infants. Independent estimates for all seven observed cases were
pooled to generate a distribution of mean YLL per fatal RV case; ccosts of third person taking care of sick child.


















Table 2 Vaccine efficacy estimates against mild, moderate and severe RV gastroenteritis
Vaccine efficacya Method Source







After first dose Calculated Calculated 89.8% (8.9 to 99.8) Calculated (Calculated from) Published data
Efficacy for mild and moderate cases after first season calculated




71.7% (50.4 to 83.9) 91.8% (84.0 to 96.3) 100% (81.8 to 100)
Second season 50.5% (24.3 to 67.7) 76.2% (63.0 to 85.0) 92.2% (65.6 to 99.1)
Third-fifth season Calculated Calculated Calculated Efficacy during third to fifth season calculated as linear
decline equal to reduction between first and second season
RV5
After first dose Calculated Calculated 88% (65 to 97) Calculated (Calculated from) Published data Efficacy after first dose and
between first and second dose for mild and moderate cases
calculated from efficacy ratios for mild, moderate, severe
during first season
[57]
After second dose Calculated Calculated 88% (69 to 96)
First season
(after third dose)
65.1% (54.1 to 73.5) 72.0% (63.2 to 78.9) 94.8% (89.4 to 97.8) (Calculated from) Published data [54,55]
Second season 49.8% (27.0 to 65.4) 58.5% (40.1 to 71.7) 90.8% (76.9 to 97.1)
Third season Calculated Calculated 100.0% (27.9 to 100) Efficacy during third season for mild and moderate cases
calculated from efficacy ratios for mild, moderate, severe
during second season
[55]
Fourth-fifth season Calculated Calculated Calculated Efficacy during third to fifth season calculated as linear decline
equal to reduction between first and second season
aVaccine efficacy was assumed equal between eligible and ineligible, data were modeled as Pert distribution; befficacy against fatal RVGE was assumed equal to efficacy for severe disease; cefficacy against nosocomial
infection based on severity distribution in original study data.
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health economic evaluations, were used in sensitivity
analysis [39]. Although there is no consensus on a cut-off
point for good value for resources, we present our results
in the context of commonly cited thresholds per QALY of
$50,000 equivalent to €35,000 [67,68]. This amount is
approximately equal to the Dutch Gross Domestic Product
per capita in 2011, the recommended threshold for highly
cost-effective interventions by the WHO [66]. In addition,
we used the unofficial threshold of €20,000/QALY
commonly applied in the Netherlands for preventive
healthcare interventions.
Total net healthcare costs for either vaccination strategy
compared to no vaccination are reported (cost-analysis) as
well as incremental cost-effectiveness ratios (ICERs),
representing costs per QALY gained comparing either strat-
egy with no vaccination. Strategies were considered cost-
effective if they generated ICER’s less than a willingness-to
-pay threshold of €35,000/QALY from the healthcare pro-
vider perspective. An ICER below €20,000/QALY was con-
sidered highly cost-effective. As additional scenario analysis,
we also calculated incremental costs and QALY’s gained for
universal RV vaccination compared to targeted vaccination.
The simulation model was built in Microsoft Excel using
add-in software @Risk, version 5.5 (Palisade). Results are
presented as means and 95% confidence interval (CI) of
simulated results, based on 10,000 iterations. Parameters
were varied simultaneously in probabilistic sensitivity ana-
lyses, performing random draws from distributions. Distri-
butions were chosen based on parameter characteristics
and level of certainty. Input parameters and their distribu-
tions with corresponding information source are presented
in Table 1. In addition, we performed one-way sensitivity
analysis to determine variables which were most influential
on model results.
Results
Rotavirus hospitalizations; observational study
Overall, 944 RV infections were identified. After excluding
six patients with asymptomatic disease and two without
medical records available, 936 patients were analyzed.
RVGE was community-acquired and nosocomial in
770 (81%) and 176 (19%) episodes, respectively [see
Additional file 1: Table S4].
In 134 patients (14%) RVGE occurred before 15 weeks of
age and would not be prevented by vaccination, unless by
herd-immunity. Prevalence of prematurity <36 weeks was
9% (n = 83), of low birth weight was 11% (n = 104) and of
complex chronic conditions at the time of RV infection was
23% (n = 219). The latter was more frequent among noso-
comial than among community-acquired infections (64%
versus 14%, P <0.0001). Most of these patients (n = 116,
53%) suffered from severe congenital pathology. Based on
weighted prevalence of prematurity, LBW and congenitalpathology among RV hospitalizations and the general infant
population, all three conditions were significantly more
common among children hospitalized for RVGE and were,
therefore, classified as high-risk for RV hospitalization
(mean RR: 1.7; 1.6; 4.4, respectively; Table 3). RVGE-related
ICU admission occurred more frequently among children
with prematurity, LBW and congenital pathology than
among otherwise healthy patients (mean RR ranging from
4.2 to 7.9). Mean length of stay was increased by 1.5 to 3.0
days and mean healthcare costs were €648 to €1,533 per
patient higher (Table 3). Results from the nested matched
case–control study demonstrated increased risks of acquir-
ing nosocomial RVGE for prematurity (aOR: 3.3, 95% CI:
1.5 to 7.3), LBW (aOR: 3.2, 95% CI: 1.5 to 7.1) and congeni-
tal pathology (aOR: 3.6, 95% CI: 1.8 to 7.0) compared to
healthy hospitalized controls (details in Additional file 1).
RV mortality
Two RV related fatalities were observed in the multi-
center study and an additional five among 214 con-
firmed RVGE episodes over six years in the second
observational study at a different tertiary care center.
All seven had congenital pathology and two patients
also had a history of LBW. One child died before 2
months of age, the remaining six children died between
2 and 14 months of age.
RV epidemiology and vaccination effects
Without vaccination, there were an estimated 75,000 (95%
CI: 58,000 to 90,000) RVGE episodes annually, with 4,870
(95%CI: 4,310 to 5,430) hospitalizations including 500
nosocomial infections among children 0 to 15 years old,
generating €11.9 (95% CI: 10.5 to 13.3) million in total
healthcare costs and €18.2 million (95% CI: 16.2 to 20.3)
when societal costs are included (Table 4). An estimated 6.5
children (95% CI: 3 to 11) die prematurely due to RV each
year in the Netherlands. A total of 257 QALY’s (95% CI:
136 to 422) are lost due to RV, of which 170 (95% CI: 50
to 330) are due to fatal RV cases.
A universal RV vaccination program (at €75 per
vaccine course per child) generates €15.2 million in
healthcare costs annually when the two-dosage RV1 and
€16.7 million when the three-dosage RV5 is used. The
difference is explained by the additional application costs of
a third RV5 dose. A total of 3,500 (95% CI: 3,050 to 3,960)
and 3,430 (95% CI: 2,980 to 3,880) RV hospitalizations are
avoided by RV1 and RV5, respectively. QALY’s gained
mount to 194 (95% CI: 83 to 348) for RV1 and 188
(95% CI: 80 to 342) for RV5. On average, 6.1 (95% CI: 3.0
to 10.2) fatal cases are avoided.
Using targeted vaccination, approximately 8% of the
infant population would be eligible for vaccination (that is,
children with one or more high-risk conditions). At €100
per vaccinated child, annual vaccination costs are €1.5
Table 3 Prevalence of high risk conditions among RV hospitalizations and their association with disease outcome and healthcare utilization
Prevalence P-valueb RRb
Observational study Weighted estimates national RV
hospitalizations (95% CI)
General infant populationa
High Risk Conditions % N % N % N
GA < 36 weeks 8.9 83 6.8 (5.1; 8.5) 347 ( 243; 451) 4.3 7617 0.005 1.7 (1.2; 2.8)
LBW 11.1 104 8.8 (6.6; 11.1) 462 (309; 615) 6.0 10545 0.014 1.6 (1.1; 2.3)
Congenital pathology 12.4 116 6.2 (4.9; 7.4) 309 (244; 374) 1.5 2719 <0.0001 4.4 (3.4; 5.4)
Healthy (N = 657) High risk conditions
GA <36 weeks (N = 83) LBW (N = 104) Congenital pathology (N = 116)
Outcome and healthcare utilization N (%) N (%) RR (95% CI) N (%) RR (95% CI) N (%) RR (95% CI)
ICU admission 4 (0.6%) 4 (4.8%) 7.9 (2.0; 31.1) 3 (2.9%) 4.7 (1.1; 20.9) 3 (2.6%) 4.2 (1.0; 18.7)
RV related death (number,%) 0 0 0 2 (1.7%) NA
Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI)
LOS (mean, SD) 3.6 (2.1) 5.2 (4.7) +1.6 (0.1; 3.0) 5.1 (4.5) +1.5 (0.3; 2.7) 6.6 (4.2) +3.0 (1.9; 4.1)
Healthcare costs (mean, SD) 2,203 (2,113) 3,001 (3,407) +798 (28; 1,568) 2,851 (3,206) +648 (−2; 1,297) 3,737 (3,500) +1,533 (867; 2,199)
aDutch birth cohort alive after one month, 2005-200838; bComparing weighted RV hospitalizations prevalence to population prevalence.
GA: gestational age; LBW: low birth weight; LOS, length of stay; RR, relative risk; RV, rotavirus; SD: standard deviation.


















Table 4 Annual results of universal and targeted RV vaccination compared to no vaccination under base-case assumptions
RV disease burden (95% CI)a RV disease costsa (€ million) Vaccination costs
(€ million)





No vaccination 74.1(57.8; 90.0) 4,870 (4,310; 5,430) 6.5 (3.2; 11.0) 257 (136; 422) 11.9 (10.5; 13.3) 18.2 (16.2; 20.3) -
Targeted RV vaccination
RV1 67.3 (51.3; 82.4) 4,370 (3,890; 4,870) 0.7(0.2; 1.6) 119 (79; 177) 10.5 (9.3; 11.8) 16.4 (14.6; 18.2) 1.5
Percent reduction 8% 10% 89% 54% 12% 10%
RV5 67.4 (51.5; 82.7) 4,384 (3,892; 4,870) 0.8 (0.3; 1.7) 121 (80; 184) 10.6 (9.4; 11.8) 16.4 (14.6; 18.2) 1.6
Percent reduction 8% 10% 88% 53% 11% 10%
Universal RV vaccination
RV1 40.6 (30.1; 51.2) 1,370 (1,150; 1,650) 0.4 (0.2; 0.8) 60 (42; 81) 3.4 (2 8; 4 1) 5.9 (5.0; 6.9) 15.2
Percent reduction 45% 72% 94% 77% 71% 67%
RV5 42.6 (31.7; 53.6) 1,440 (1,210; 1,710) 0.5(0.2; 0.9) 66 (45; 91) 3.6 (3.1; 4.3) 6.3 (5.3; 7.3) 16.7
Percent reduction 43% 70% 92% 75% 70% 65%
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95% CI: 420 to 590) or 490 (RV5, 95% CI: 410 to 570) hos-
pitalizations are avoided while the number of avoided fatal
infections is similar to results for universal RV vaccination
(5.8 cases, 95% CI: 3.0 to 9.5). A total of 137 QALY’s are
gained.
As outcome results for either vaccine were almost
identical, further analyses presented are based on RV1
vaccination with results for RV5 available in Additional
file 1: Table S5.
Net healthcare costs (defined as vaccination costs
minus healthcare savings) were compared for different
scenarios (Figure 1). Undiscounted annual net healthcare
costs of universal RV vaccination compared to no vac-
cination varied between €3.7 and €9.6 million, depending
on assumptions about vaccine price, herd-immunity
and vaccine coverage. Results of targeted vaccination
versus no vaccination varied between net savings of
€0.1 million up to maximum costs of €0.5 million.
Comparing the free market vaccine price in both
strategies resulted in a difference of €16 million annu-
ally (€16.9 versus €0.7 million for universal and targeted
vaccination, respectively).
Universal RV vaccination compared to no vaccination
is unlikely to be cost-effective from the healthcare provider
perspective at a willingness-to-pay threshold of €35,000/
QALY gained (Figure 2 and Additional file 1: Figure S2).
Among the different scenarios analyzed for universal RV
vaccination, the only cost-effective scenario included both
herd immunity and caretaker QALY losses and assumed a
vaccine price of €60/child (ICER: €21,309/QALY, 95% CI:
11,079 to 36,047). Targeted RV vaccination is highly cost-Figure 1 Comparison of annual net healthcare costs for RV vaccinatio
(A) and targeted RV vaccination (B) compared to no vaccination under diff
results when the vaccine price per course is €75 per child, coverage is 88%
represent results for a vaccine price per course of €60 and €95 per vaccina
unvaccinated children. A scenario with herd immunity effects was not inclu
vaccine price, coverage of 97% and presence of herd immunity. ‘Worst cas
immunity. ‘Vaccine Free Market Price’ shows results when the current listed
interval; RV: rotavirus.effective in all scenarios tested. The best case scenario is
dominant with net discounted mean savings of €60,000 and
67 QALY’s gained compared to no vaccination. The
maximum ICER for targeted vaccination is €8,700/QALY
when using the free market price (Figure 2). Moving from
targeted vaccination to universal RV vaccination under
base-case assumptions generates €5.3 million in mean
incremental costs and 33 additional QALY’s gained. The
mean ICER for universal versus targeted vaccination is
€162,000/QALY using a healthcare provider perspective
(Table 5). Outcome results from the societal perspective
and analyses based on different discount rates are provided
in Additional file 1: Table S6.
Cost-effectiveness was most sensitive to the estimated
mortality rate. We, therefore, included a threshold analysis
to identify the cut-off value of the parameter at which
targeted vaccination would no longer be cost-effective.
Targeted vaccination remained highly cost-effective up to a
reduction of 90% in mortality rate, which translates to less
than 1 RV death per year (Figure 3).
Choosing between competing strategies requires
consideration of cost-effectiveness acceptability curves,
which visualize the probability of cost-effectiveness
dependent on the willingness-to-pay for health benefits.
At a threshold of €35,000/QALY, we estimate the probabil-
ity of cost-effectiveness of universal RV vaccination under
base-case assumptions from the healthcare provider
perspective to be 6%, and 71% from a societal perspective
(Figure 4). The probability of cost-effectiveness of targeted
vaccination both at the €35,000/QALY and €20,000/QALY
thresholds is 100% for both healthcare provider and societal
perspectives.n strategies. Net undiscounted annual healthcare costs for universal
erent assumptions and corresponding 95% CI. ‘Basecase’ represents
, and no herd immunity is present. ‘Vaccine price low’ and ‘high’
ted child, respectively. ‘Herd immunity’ includes protection of
ded for targeted vaccination. ‘Best case’ represents results from a low
e’ represents a high vaccine price, coverage of 65% and no herd
vaccine price is used without any tender effects. CI:confidence
Figure 2 Comparison of cost-effectiveness of RV vaccination strategies. Cost per QALY gained (mean and 95% CI) for universal (A) and
targeted RV vaccination (B), using a healthcare provider perspective and a discount rate of 3% for both costs and effects, under different
assumptions. ‘Basecase’ represents results when the vaccine price per course is €75 per child, coverage is 88%, and no herd immunity is present.
‘Vaccine price low’ and ‘high’ represent results for vaccine price per course of €60 and €95 per vaccinated child, respectively, for universal RV
vaccination and vaccine price per course of €80 and €120 for targeted RV vaccination. ‘Herd immunity’ includes protection of unvaccinated children
(only used in universal RV vaccination). ‘QALY2’ represents results when QALY loss of caretakers is taken into account. ‘Best case’ represents results from
a low vaccine price, coverage of 97%, including caretaker QALY’s and presence of herd immunity. ‘Worst case’ represents a high vaccine price,
coverage of 65%, no caretaker QALY’s included and no herd immunity. ‘Vaccine Free Market Price’ shows results when the current listed vaccine price
is used without any tender effects under base-case assumptions. CI: confidence interval; QALY: quality-adjested life year; RV: rotavirus.
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Based on detailed Dutch epidemiological data analyzed
in an age-structured, discrete-time event, stochastic multi-
cohort model, we conclude that targeted RV vaccination of
high-risk infants is highly cost-effective and potentially
cost-saving in the Netherlands. Cost-effectiveness estimates
were most sensitive to RV mortality rates, but targeted RV
vaccination remained cost-effective when mortality would
be 90% lower than observed.
In our analysis, universal RV vaccination was not consid-
ered cost-effective from the healthcare provider perspective
and would only become cost-effective when herd-immunity
and caretaker QALY losses were included and if vaccine
prices would be at most €60/child. These results are in line
with results from other European cost-effectivenessTable 5 Mean costs per different health outcome comparing
assumptions (RV1) using a healthcare provider perspective
Targeted versus no vaccination Universa
Costs (€)a
per case avoided 21 174
per life year saved 2,400 96,600
per fatal case 0.03b 1.03b
per QALY gained 2,600 60,200
aA discount rate of 3% was used for both costs and effects; b€million. QALY, qualityanalyses that have used comparable methodology and
QALY loss estimates for RVGE. Universal RV vaccination
was not considered cost-effective from the healthcare
provider perspective in Belgium, England and Wales,
France, the Netherlands and Ireland, and was cost-effective
in Finland only [9,69]. Our analysis demonstrated that
universal RV vaccination could, however, be considered
cost-effective from the societal perspective at the €35,000/
QALY threshold. These findings differ somewhat from
previous economic analyses of universal RV vaccination in
the Netherlands [9,10,45] which can be explained by the
updated and more reliable parameter estimates used.
Incidence and costs of RV hospitalizations in the
Netherlands determined in our study are comparable to
estimates from Germany, Finland and the UK and anotherdifferent RV vaccination strategies under base-case





-adjusted life year; RV, rotavirus.
Figure 3 Mean cost per QALY gained by universal (grey line) and targeted (black line) RV vaccination, using a healthcare provider
perspective and a discount rate of 3% for both costs and effects, as a function of change in mortality rate between 0% and −100%
(that is, no mortality at all) compared to baseline. QALY: quality-adjusted life year; RV: rotavirus.
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http://www.biomedcentral.com/1741-7015/11/112recent Dutch observational study [65,70-72]. Previously,
lower incidence and cost estimates were derived for the
Netherlands by using indirect methods combining sentinel
laboratory data and hospital discharge codes [73,74]. The
accuracy and completeness of methods using discharge
codes has been criticized and depends on local coding prac-
tices [75-77]. In addition, we could include recent estimates
of parental work loss in children hospitalized for RV [51].
Our analysis did not account for potential costs and
QALY losses associated with vaccination induced
intussusception. Based on observed intussusception
risks attributable to RV vaccination in different popu-
lations, 0 to 9 additional cases would occur each year
in the Netherlands when universal RV vaccination is
implemented [78-86]. Clearly, this could have a nega-
tive impact on cost-effectiveness, although overall
effects may be small. Furthermore, the recent reports
on an increased risk of intussusception after the first doseFigure 4 Probability of willingness-to-pay at different thresholds for u
under base-case assumptions showing results for both healthcare proof RV vaccine may raise concerns about exposing healthy
children at low risk of RV-related complications to
vaccination risks [87,88].
Our study confirms that prematurity, LBW and
congenital pathology are important risk factors for
RV hospitalization and increased healthcare needs.
Furthermore, we observed RV mortality exclusively
among patients with any of these high-risk conditions.
Although absolute numbers were low, similar observa-
tions in other European and US studies and the asso-
ciation between diarrhea-related mortality and birth
weight confirm the existence of differential mortality
risks [17,19,30-32]. Of note, in five out of seven pa-
tients who succumbed the underlying illness rather
than RV was stated as the cause of death in death-
records. Yet, in these patients RV caused a profound med-
ical deterioration leading to premature death, as confirmed
by expert review of case histories. These findings suggestniversal and targeted RV vaccination versus no vaccination
vider (HP) and societal perspective (SP). RV: rotavirus.
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http://www.biomedcentral.com/1741-7015/11/112that among children with severe underlying condi-
tions fatal RV disease is underreported.
Although limited data are available on vaccine safety
and efficacy among high risk patients, protection provided
by RV vaccine was comparable in premature and non-
premature infants without additional safety risk [89-91].
Current recommendations support RV vaccination in
preterm infants and also in those with preexisting
underlying disease, including gastrointestinal disease,
in non-acute phases of illness [3,5,92]. Recently, it
was shown that RV vaccination among short bowel
patients is well tolerated [93].
Targeted RV vaccination does not offer the potential
benefits of herd-protection, which has been described after
implementation of universal RV vaccination. Observed
effects among unvaccinated individuals ranged from 0 to
72% with substantial differences between consecutive years
and effects declining with increasing age [46,58,59]. As
severe RVGE occurs mainly in those <5 years old, herd-
immunity could be a transient effect post-implementation,
which disappears when coverage rates among this age-
group approach 100%. Therefore, herd-immunity effects on
the population level are difficult to predict [47]. Continued
surveillance may provide more insights in coming years.
Naturally, our findings and conclusions may not hold
for countries with high RV mortality among the general
infant population and with higher RVGE incidences. In
such countries universal RV vaccination remains the
recommended approach.
Conclusions
Universal RV vaccination is the preferred strategy to
decrease the high disease burden among young chil-
dren caused by RV in European countries and else-
where, but is probably not cost-effective from the
healthcare provider perspective. Targeted RV vaccin-
ation of high-risk infants is highly cost-effective and
can nearly eliminate RV mortality in developed coun-
tries with very limited impact on healthcare budgets. We,
therefore, encourage policy makers in countries without
RV vaccination programs to prioritize RV vaccination for
high-risk infants.
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